Abstract
Background: Human milk oligosaccharide (HMO) is a third most abundant component in breast milk. HMOs are molecules naturally tailored to the need of an infant. They protect infants from diseases, foster healthy gastrointestinal systems, reinforce fledgling immune function, and promote early brain development. Supplement HMOs to infant formula, which lack this critical element, would substantially improve the function of formula. Overwhelming evidence also indicate that HMOs can be used for the treatment of arthritis and related autoimmune disease, and inhibition of bacteria adhesion or as potential prebiotics. The prospect of using HMO in these applications has stimulated worldwide interest in developing synthesis technology for these valuable products.
Methods: As the quantities extracted from human milk are limited, and chemical synthesis methods are time-consuming, costly, and complex, biotechnological approach, involving either enzyme catalysis or metabolically engineered bacteria is preferred. In this review, we highlight the most recent advances in the synthesis technologies, as disclosed in patents and patent applications, and analyze these technologies against those reported in literatures.
Conclusion: Significant progress has been made over the past decade, especially in whole-cell biocatalysis for smaller HMOs. Significant challenges remain for larger and more complex HMOs.
Keywords: Human milk oligosaccharide, prebiotics, glycosyltransferases, glycosidases, microbial fermentation, metabolic engineering.
Graphical Abstract
Recent Patents on Biotechnology
Title:Recent Technology Development for the Biosynthesis of Human Milk Oligosaccharide
Volume: 12 Issue: 2
Author(s): Ningzi Guan and Rachel Chen*
Affiliation:
- School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta-30332, GA,United States
Keywords: Human milk oligosaccharide, prebiotics, glycosyltransferases, glycosidases, microbial fermentation, metabolic engineering.
Abstract: Background: Human milk oligosaccharide (HMO) is a third most abundant component in breast milk. HMOs are molecules naturally tailored to the need of an infant. They protect infants from diseases, foster healthy gastrointestinal systems, reinforce fledgling immune function, and promote early brain development. Supplement HMOs to infant formula, which lack this critical element, would substantially improve the function of formula. Overwhelming evidence also indicate that HMOs can be used for the treatment of arthritis and related autoimmune disease, and inhibition of bacteria adhesion or as potential prebiotics. The prospect of using HMO in these applications has stimulated worldwide interest in developing synthesis technology for these valuable products.
Methods: As the quantities extracted from human milk are limited, and chemical synthesis methods are time-consuming, costly, and complex, biotechnological approach, involving either enzyme catalysis or metabolically engineered bacteria is preferred. In this review, we highlight the most recent advances in the synthesis technologies, as disclosed in patents and patent applications, and analyze these technologies against those reported in literatures.
Conclusion: Significant progress has been made over the past decade, especially in whole-cell biocatalysis for smaller HMOs. Significant challenges remain for larger and more complex HMOs.
Export Options
About this article
Cite this article as:
Guan Ningzi and Chen Rachel *, Recent Technology Development for the Biosynthesis of Human Milk Oligosaccharide, Recent Patents on Biotechnology 2018; 12 (2) . https://dx.doi.org/10.2174/1872208311666170531110721
DOI https://dx.doi.org/10.2174/1872208311666170531110721 |
Print ISSN 1872-2083 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4012 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Computational Studies Applied to Anti-inflammatory Drug Discovery: A Review
Current Organic Chemistry Effects of Secondhand Smoke on Thyroid Function
Inflammation & Allergy - Drug Targets (Discontinued) Genetics and Ulcerative Colitis: What are the Clinical Implications?
Current Drug Targets Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases
Current Molecular Medicine Defining Peptide Sequences: From Antigenicity to Immunogenicity Through Redundancy
Current Pharmacogenomics The Unique Inhibitory IgG Receptor--FcγRIIb
Protein & Peptide Letters Lipid-Based Nanocarriers for RNA Delivery
Current Pharmaceutical Design Functional Variants of the Interleukin-23 Receptor Gene in Non-Gastrointestinal Autoimmune Diseases
Current Medicinal Chemistry S1P Receptor Modulators in Cell Trafficking and Therapeutics
Current Immunology Reviews (Discontinued) Modulation of TNF Receptor Family Members to Inhibit Autoimmune Disease
Current Drug Targets - Inflammation & Allergy DNA Vaccines: A Mini Review
Recent Patents on DNA & Gene Sequences Autoantibodies in Autoimmune Diseases
Current Pharmaceutical Design The IL-12 Family of Cytokines in Infection, Inflammation and Autoimmune Disorders
Inflammation & Allergy - Drug Targets (Discontinued) Lysophospholipid Receptors as Potential Drug Targets in Tissue Transplantation and Autoimmune Diseases
Current Pharmaceutical Design Inhibitor at the Gates, Inhibitor in the Chamber: Allosteric and Competitive Inhibitors of the Proteasome as Prospective Drugs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Purine Nucleoside Phosphorylase: A Potential Target for the Development of Drugs to Treat T-Cell- and Apicomplexan Parasite-Mediated Diseases
Current Drug Targets Estrogen, Immunity & Autoimmune Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Multivalent Compounds for Antigen-Specific B Cell Tolerance and Treatment of Autoimmune Diseases
Current Medicinal Chemistry Regulation of B Cell Activation by PECAM-1: Implications for the Development of Autoimmune Disorders
Current Pharmaceutical Design Dendritic Cells in Autoimmune Liver Diseases
Current Immunology Reviews (Discontinued)